COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2019.01.015
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?

Clinical Medicine Insights: Oncology
Oncology
2011English

Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2018English

Rationale for Targeted Therapies and Potential Role of Pazopanib in Advanced Renal Cell Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2010English

Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients With Advanced Renal Cell Carcinoma Treated With Pazopanib

Oncology
MedicineCancer ResearchOncology
2015English

Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma

Oncotarget
Oncology
2016English

Real-World Clinical Outcomes of Pazopanib Immediately Following Immunotherapy Discontinuation for the Treatment of Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2020English

Clinical Outcome of Third-Line Pazopanib in a Patient With Metastatic Renal Cell Carcinoma

Case Reports in Oncological Medicine
Oncology
2015English

Pazopanib Has Equivalent Anti-Tumor Effectiveness and Lower Total Costs Than Sunitinib for Treating Metastatic or Advanced Renal Cell Carcinoma: A Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy